Colleen Niswender
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials. Read MoreDec 4, 2023
-
Colleen Niswender lands national award, several grants for Rett syndrome research
Colleen Niswender, associate professor of pharmacology and director of molecular pharmacology for the Warren Center for Neuroscience Drug Discovery, was awarded the ASPET Scientific Achievement Award in Drug Discovery and Development for her work in the development of novel treatments for neurological and psychiatric disorders. Read MoreMar 22, 2022
-
Vanderbilt inks collaboration with precision neuroscience company Neumora to continue development of investigational treatment for neuropsychiatric disorders
Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read MoreFeb 22, 2022
-
A potential new approach for the treatment of schizophrenia
Researchers discover how a protein may treat schizophrenia, including reversing working memory deficits, a hallmark of schizophrenia for which there is currently no treatment. Read MoreDec 8, 2021
-
Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders
Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read MoreJun 16, 2020
-
Drug discovery efforts may lead to new Rett syndrome treatments
Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit. Read MoreAug 24, 2017
-
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects. Read MoreAug 7, 2017
-
VUMC’s Rett Syndrome Clinic lands national recognition
Vanderbilt’s Rett Syndrome Clinic has been named a Rett Syndrome Clinical Research Center of Excellence by Rettsyndrome.org. Read MoreNov 17, 2016
-
Study reveals possible ‘dimmer switch’ drug for Rett syndrome
Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit. Read MoreMar 3, 2016
-
Autism Speaks grant boosts Rett syndrome research
Colleen Niswender, Ph.D., research associate professor of Pharmacology, has received a three-year, $450,000 grant from the autism science and advocacy organization Autism Speaks to support studies investigating a possible new treatment for Rett syndrome. Read MoreJan 23, 2014
-
Drug-like molecules aimed at improving treatment of Parkinson’s
Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects. Read MoreSep 30, 2011
-
New drug-like molecules could improve schizophrenia treatment
The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia. Read MoreSep 22, 2011
-
Milestone in development of new treatment for ‘fragile X’
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism. Read MoreSep 15, 2011
-
Neuroscience drug discovery center opens at Vanderbilt
Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain. Read MoreMar 11, 2011